Molterfin (Buprenorphine)

Buprenorphine, the active ingredient in Molterfin, is a partial mu‑opioid receptor agonist presented as a sublingual formulation for sublingual administration. It provides analgesic effects for moderate to severe pain and helps alleviate withdrawal symptoms in individuals with opioid dependence, offering a ceiling effect that reduces the risk of respiratory depression.\n\nGNH India supplies Molterfin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Buprenorphine acts on the opioid receptor system and is indicated for the following clinical situations:\n\n- Pain management: provides analgesia for moderate to severe chronic pain, with a ceiling effect on respiratory depression.\n- Opioid dependence treatment: reduces withdrawal symptoms and cravings in patients with opioid use disorder, facilitating maintenance therapy.\n- Palliative care: offers sustained pain relief in terminal illness when other opioids are insufficient.

Buprenorphine may cause a range of adverse reactions, which are categorized by frequency and severity.\n\nCommon Side Effects:\n- Nausea\n- Constipation\n- Headache\n- Dizziness\n- Sedation\n- Dry mouth\n\nSerious or Rare Side Effects:\n- Respiratory depression\n- Severe hypotension\n- QT interval prolongation\n- Adrenal insufficiency\n- Allergic reactions (rash, angioedema)\n- Acute opioid withdrawal if abruptly discontinued

When prescribing or dispensing Molterfin, consider the following precautions:\n\n- Assess respiratory function: monitor patients with compromised breathing or chronic lung disease.\n- Evaluate hepatic function: use caution and consider dose adjustment in severe liver impairment.\n- Avoid concomitant CNS depressants: increased risk of sedation and respiratory depression.\n- Use caution in elderly patients: heightened sensitivity to opioid effects may require lower initial doses.\n- Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Buprenorphine can interact with several medication classes; awareness of the interaction level guides clinical decisions.\n\nMajor Interactions (Avoid):\n- CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase buprenorphine plasma concentrations.\n- Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.\n- Other opioids: potential for additive opioid effects.\n- Certain antidepressants (e.g., SSRIs, SNRIs): monitor for serotonin syndrome.